TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQAEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the “Transaction”), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQAEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”).
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQAEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows:
TORONTO and EDMONTON, Alberta, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQAEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy advisor Institutional Shareholder Services Inc. ("ISS") recommended that both companies’ securityholders vote FOR the all-stock merger of equals transaction (the “Transaction”) pursuant to the terms announced on December 14, 2023.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aeterna Zentaris Inc. (NASDAQAEZS) and Ceapro Inc. is fair to Aeterna shareholders.
AEterna Zentaris (NASDAQAEZS) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:05 AM. Here's what investors need to know about the announcement.
Gainers Applied Blockchain, Inc. (NASDAQAPLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Gainers Applied Blockchain, Inc. (NASDAQAPLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Gainers Applied Blockchain, Inc. (NASDAQAPLD) rose 32.1% to $1.40 in pre-market trading after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Gainers Seritage Growth Properties (NYSESRG) rose 35.7% to $8.25 in pre-market trading after gaining around 10% on Thursday. Seritage Growth Properties filed its preliminary proxy materials with the U.S. Securities and Exchange Commission.
Gainers Revelation Biosciences, Inc. (NASDAQREVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Gainers Revelation Biosciences, Inc. (NASDAQREVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Gainers Allena Pharmaceuticals, Inc. (NASDAQALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
AEterna Zentaris (NASDAQAEZS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AEterna Zentaris reported in-line EPS of $-0.02 versus an estimate of $-0.02.
